AlphAIalphai — Financial news for AI agents
financialcontent.comAUG 44 min read$PLUS

ePlus (NASDAQ:PLUS) Surprises With Q2 CY2026 Sales

ePlus (NASDAQ:PLUS) reported Q2 CY2026 revenue of $649.1 million, up 1.9% year on year, exceeding market expectations. Non-GAAP profit was $1.28 per share, 11.8% above analysts’ consensus. The company cited extended lead times and shipment delays tied to an ongoing memory chip shortage.

Original reporting
financialcontent.com
Published Aug 4, 2026, 10:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 4, 2026, 10:05 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
ePlus (NASDAQ:PLUS) Surprises With Q2 CY2026 Sales — source image
Source · financialcontent.com
Decision brief

The 30-second read

$PLUSBullishMed
01

Why it matters

Q2 results beat consensus on both sales and adjusted EPS, while management attributes some execution friction to extended lead times from the memory chip shortage, creating uncertainty around second-half revenue conversion.

02

Market read

Traders can reassess near-term expectations for IT services delivery and margin stability based on the beat versus consensus and the stated chip shortage headwind.

03

What to watch

The article mentions extended lead times and shipment delays but does not quantify their magnitude or whether backlog converts to revenue cleanly in the second half.

Relevance 7/10Novelty 7/10Timing: after-hours/late-day earnings coverage on 2026-08-04

Background

ePlus is an IT solutions provider that also offers professional services and financing, and it cited a challenging YoY comparison plus memory-chip-driven delivery delays.

Company-level read

Ticker impact

$PLUSBullishMedium confidence
Context

ePlus reported Q2 CY2026 sales of $649.1M (+1.9% YoY) and non-GAAP EPS $1.28, beating revenue and EPS expectations.

Expected impact

Near-term upside bias versus estimates, with follow-through dependent on whether chip-related delays ease in the second half.

Evidence & confidence

The article provides concrete Q2 results versus consensus and a specific operational headwind (memory chip shortage) that can affect subsequent quarters.

Market effects

Sector

Signals resilience in IT solutions and services demand, but highlights ongoing hardware supply-chain constraints that can pressure delivery schedules.

Regional

No specific regional demand or macro linkage provided.

Global

Memory chip shortage is a global supply-chain factor that can affect IT infrastructure delivery timelines.

Counterpoint

What could challenge this read

The revenue growth is modest (+1.9% YoY) and the margin discussion suggests limited operating leverage, so the beat may not translate into sustained upside.

Key entities

  • company
    ePlus

    Reported Q2 CY2026 sales of $649.1M and non-GAAP EPS of $1.28, and discussed shipment delays tied to the memory chip shortage.

  • executive
    Mark Marron

    CEO and President of ePlus, quoted on execution, booked/open orders, and supply-chain delays.

Read at source← All news

Related articles

AUG 5
$PLUSMedAI 8/10

Why ePlus (PLUS) Shares Are Plunging Today

ePlus (NASDAQ: PLUS) shares fell about 5% after the company reported Q2 2026 results. Revenue rose 1.9% year over year to $649.1 million and adjusted EPS was $1.28, both above Wall Street estimates. Despite the beat, investors focused on declining adjusted operating and free cash flow margins and a forecast of about 2% full-year EPS growth. Shares later traded near $92.31.

financialcontent.com4 min
AUG 4
$PLUSMed

EPLUS INC (PLUS): Results of Operations and Financial Condition

EPLUS INC (PLUS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 5 ef20079242_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 ePlus Reports First Quarter Fiscal Year 2027 Financial Results Managed Services Delivers Strong Performance and Increases Recurring Revenue ~ Reiterates Fiscal 2027 Guidance ~ First Quarter of Fiscal Year 2027 ● Net sales

SEC EDGAR 8-K6 min
AUG 4
$PLUSMed

ePlus Reports First Quarter Fiscal Year 2027 Financial Results

ePlus (NASDAQ: PLUS) reported Q1 FY2027 results for the three months ended June 30, 2026. Net sales rose 1.0% to $649.1 million and services revenue rose 2.6% to $119.4 million, while gross profit fell 1.5% to $151.3 million. Net earnings from continuing ops declined 5.4% to $30.3 million and adjusted EBITDA fell 9.2% to $47.8 million. The company reiterated FY2027 mid-single-digit growth guidance and declared a $0.27 quarterly dividend.

prnewswire.com6 min
JUL 13
$PLUSMed

PageGroup & Oxford Nanopore: Markets live

PageGroup shares rose over 11% after it reported Q2 gross profit of £198m, down 0.2% year on year but ahead of analyst expectations, and said it sees signs of market normalisation. ME Group International gained about 11% after interim results showed flat £154m sales. Plus500 shares fell on weaker cash margin, and Oxford Nanopore dropped 12% after H1 sales missed expectations at £116.5m.

investorschronicle.co.uk6 min
MAY 28
$PLUSMedAI 8/10

ePlus (NASDAQ:PLUS) Issues Earnings Results

ePlus (NASDAQ:PLUS) reported quarterly EPS of $1.00, slightly above analysts’ $0.98 consensus, and revenue of $576.17 million versus $569.25 million expected, according to FiscalAI. The stock fell $0.54 to $88.65 on Thursday. Institutional investors hold 93.8%.

dailypolitical.com4 min